1039025-10-9

Basic information

• Product Name: N-(2,4,6-trimethylbenzenesulfonyl)-L-phenylalanine methyl ester
• Synonyms: N-(2,4,6-trimethylbenzenesulfonyl)-L-phenylalanine methyl ester
• CAS NO: 1039025-10-9
• Molecular Weight: 361.462
• Mol File: 1039025-10-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(2,4,6-trimethylbenzenesulfonyl)-L-phenylalanine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4,6-trimethylbenzenesulfonyl)-L-phenylalanine methyl ester(1039025-10-9)
• EPA Substance Registry System: N-(2,4,6-trimethylbenzenesulfonyl)-L-phenylalanine methyl ester(1039025-10-9)

Safety Data

• Hazardous Substances Data: 1039025-10-9(Hazardous Substances Data)

Upstream product

• 63-91-2 L-phenylalanine 
• 773-64-8 2-mesitylenesulphonyl chloride 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 13033-84-6 D-phenylalanine methyl ester hydrochloride 

Downstream Products

• 182880-90-6 (S)-N-(2,4,6-trimethylphenylsulfonyl)phenylalaninol 
• 1401712-46-6 5-benzyl-1-mesitylenesulfonyl-3-phenylimidazolidin-2,4-dione 
• 1401712-51-3 C₂₂H₂₆N₂O₄S 

Relevant articles and documents

Design, synthesis of new chiral fluorine-containing β-hydroxysulfonamides from natural amino acids and study of their anti-inflammatory and analgesic activities

A series of new chiral fluorine-containing β-hydroxysulfonamides were conveniently synthesized in three steps, starting from natural L-amino acids, and evaluated for their anti-inflammatory and analgesic activities. The structures of these compounds were supported by FT-IR, 1H, 13C and 19F NMR, elemental analysis and HRMS. Among the tested compounds, 4c, 4g and 4h exhibited promising anti-inflammatory activity. Moreover, compound 4h showed a significant analgesic activity. The structure–activity relationships of selected compounds were discussed.

Synthesis of a β-tetrapeptide analog as a mother compound for the development of matrix metalloproteinase-2-imaging agents

Matrix metalloproteinase-2 (MMP-2) is an attractive target for the diagnosis of cancer and atherosclerosis in nuclear imaging. A cyclic decapeptide, cCTTHWGFTLC (cCTT), has been used as the mother compound for the development of MMP-2-imaging agents with high potency and selectivity. Most of radiolabeled derivatives of cCTT currently developed for in vivo studies of MMP-2, however, suffer from low accumulation in the target tissues, such as tumors. For enhanced in vivo stability and tissue penetration, we designed a linear β-tetrapeptide analog, H-β3-Phe-β-Ala- β3-Trp-β3-His-OH (1), to mimic cCTT. The component β-amino acids were prepared by reduction of N-protected α-amino acid methyl esters to the alcohols, followed by conversion into the cyanides, and subsequent hydrolysis. Compound 1 was obtained from these β-amino acids by the conventional solution method. In MMP-2 inhibition assay, compound 1 displayed desirably significant inhibition, which was comparable to cCTT. These findings suggest that compound 1 may serve as a mother compound in the design and development of in vivo MMP-2-imaging agents.